Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma
The Chinese traditional medicine KangXianYiAi formula (KXYA) is used to treat hepatic disease in the clinic. Here we aim to confirm the therapeutic effects and explore the pharmacological mechanisms of KXYA on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). We first collected and ana...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.985084/full |
| _version_ | 1798004567172972544 |
|---|---|
| author | Xu Cao Hening Chen Zhiguo Li Xiaoke Li Xiaoke Li Xianzhao Yang Xianzhao Yang Qiushuo Jin Qiushuo Jin Yijun Liang Jiaxin Zhang Jiaxin Zhang Meiyue Zhou Ningyi Zhang Guang Chen Guang Chen Hongbo Du Hongbo Du Xiaobin Zao Xiaobin Zao Yong’an Ye Yong’an Ye |
| author_facet | Xu Cao Hening Chen Zhiguo Li Xiaoke Li Xiaoke Li Xianzhao Yang Xianzhao Yang Qiushuo Jin Qiushuo Jin Yijun Liang Jiaxin Zhang Jiaxin Zhang Meiyue Zhou Ningyi Zhang Guang Chen Guang Chen Hongbo Du Hongbo Du Xiaobin Zao Xiaobin Zao Yong’an Ye Yong’an Ye |
| author_sort | Xu Cao |
| collection | DOAJ |
| description | The Chinese traditional medicine KangXianYiAi formula (KXYA) is used to treat hepatic disease in the clinic. Here we aim to confirm the therapeutic effects and explore the pharmacological mechanisms of KXYA on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). We first collected and analyzed clinical data of 40 chronic hepatitis B (CHB) patients with precancerous liver lesions under KXYA treatment. Then, the cell viability, migration, cell cycle, and apoptosis of HepAD38 cells with KXYA treatment were examined. Next, we performed network pharmacological analysis based on database mining to obtain the key target pathways and genes of KXYA treatment on HBV-related HCC. We finally analyzed the expression of the key genes between normal and HBV-related HCC tissues in databases and measured the mRNA expression of the key genes in HepAD38 cells after KXYA treatment. The KXYA treatment could reduce the liver nodule size of CHB patients, suppress the proliferation and migration capabilities, and promote apoptosis of HepAD38 cells. The key pathways of KXYA on HBV-related HCC were Cancer, Hepatitis B, Viral carcinogenesis, Focal adhesion, and PI3K-Akt signaling, and KXYA treatment could regulate the expression of the key genes including HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1. The KXYA exhibited a curative effect via inhibiting proliferation, migration, and promoting apoptosis of HBV-related HCC and the pharmacological mechanism was related to the regulation of the expression of HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1. |
| first_indexed | 2024-04-11T12:25:38Z |
| format | Article |
| id | doaj.art-49c002ce77f0494894a0fe09a5485762 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T12:25:38Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-49c002ce77f0494894a0fe09a54857622022-12-22T04:23:57ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.985084985084Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinomaXu Cao0Hening Chen1Zhiguo Li2Xiaoke Li3Xiaoke Li4Xianzhao Yang5Xianzhao Yang6Qiushuo Jin7Qiushuo Jin8Yijun Liang9Jiaxin Zhang10Jiaxin Zhang11Meiyue Zhou12Ningyi Zhang13Guang Chen14Guang Chen15Hongbo Du16Hongbo Du17Xiaobin Zao18Xiaobin Zao19Yong’an Ye20Yong’an Ye21Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaBeijing Fengtai Hospital of Integrated Traditional and Western Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaKey Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaKey Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Liver Diseases, Beijing University of Chinese Medicine, Beijing, ChinaThe Chinese traditional medicine KangXianYiAi formula (KXYA) is used to treat hepatic disease in the clinic. Here we aim to confirm the therapeutic effects and explore the pharmacological mechanisms of KXYA on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). We first collected and analyzed clinical data of 40 chronic hepatitis B (CHB) patients with precancerous liver lesions under KXYA treatment. Then, the cell viability, migration, cell cycle, and apoptosis of HepAD38 cells with KXYA treatment were examined. Next, we performed network pharmacological analysis based on database mining to obtain the key target pathways and genes of KXYA treatment on HBV-related HCC. We finally analyzed the expression of the key genes between normal and HBV-related HCC tissues in databases and measured the mRNA expression of the key genes in HepAD38 cells after KXYA treatment. The KXYA treatment could reduce the liver nodule size of CHB patients, suppress the proliferation and migration capabilities, and promote apoptosis of HepAD38 cells. The key pathways of KXYA on HBV-related HCC were Cancer, Hepatitis B, Viral carcinogenesis, Focal adhesion, and PI3K-Akt signaling, and KXYA treatment could regulate the expression of the key genes including HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1. The KXYA exhibited a curative effect via inhibiting proliferation, migration, and promoting apoptosis of HBV-related HCC and the pharmacological mechanism was related to the regulation of the expression of HNF4A, MAPK8, NR3C1, PTEN, EGFR, and HDAC1.https://www.frontiersin.org/articles/10.3389/fphar.2022.985084/fulltraditional Chinese medicineHBV-related hepatocellular carcinomanetwork pharmacologicalbioinformaticsKangXianYiAi formula |
| spellingShingle | Xu Cao Hening Chen Zhiguo Li Xiaoke Li Xiaoke Li Xianzhao Yang Xianzhao Yang Qiushuo Jin Qiushuo Jin Yijun Liang Jiaxin Zhang Jiaxin Zhang Meiyue Zhou Ningyi Zhang Guang Chen Guang Chen Hongbo Du Hongbo Du Xiaobin Zao Xiaobin Zao Yong’an Ye Yong’an Ye Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma Frontiers in Pharmacology traditional Chinese medicine HBV-related hepatocellular carcinoma network pharmacological bioinformatics KangXianYiAi formula |
| title | Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma |
| title_full | Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma |
| title_fullStr | Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma |
| title_full_unstemmed | Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma |
| title_short | Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma |
| title_sort | network pharmacology and in vitro experiments based strategy to investigate the mechanisms of kangxianyiai formula for hepatitis b virus related hepatocellular carcinoma |
| topic | traditional Chinese medicine HBV-related hepatocellular carcinoma network pharmacological bioinformatics KangXianYiAi formula |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.985084/full |
| work_keys_str_mv | AT xucao networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT heningchen networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT zhiguoli networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xiaokeli networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xiaokeli networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xianzhaoyang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xianzhaoyang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT qiushuojin networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT qiushuojin networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT yijunliang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT jiaxinzhang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT jiaxinzhang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT meiyuezhou networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT ningyizhang networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT guangchen networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT guangchen networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT hongbodu networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT hongbodu networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xiaobinzao networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT xiaobinzao networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT yonganye networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma AT yonganye networkpharmacologyandinvitroexperimentsbasedstrategytoinvestigatethemechanismsofkangxianyiaiformulaforhepatitisbvirusrelatedhepatocellularcarcinoma |